A Study of LY3039478 in Japanese Participants With Advanced Solid Tumors

Launched by ELI LILLY AND COMPANY · Jul 15, 2016

Keywords

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Histological or cytological evidence of a diagnosis of solid tumor that is advanced and/or metastatic.
• • In the judgment of the investigator, participants must be appropriate candidates for experimental therapy after available standard therapies have failed or for whom standard therapy is not appropriate.
• • Performance status of less than or equal to (≤) 1 on the Eastern Cooperative Oncology Group (ECOG) scale.
• • Adequate organ function, including hematologic, hepatic, and renal.
• • Estimated life expectancy of greater than or equal to (≥) 12 weeks.
• Exclusion Criteria:
• • Received previous therapy for cancer within 14 or 21 days of the initial dose of study drug for a nonmyelosuppressive or myelosuppressive agents, respectively.
• • Have serious preexisting medical conditions.
• • Have current or recent (within 3 months of study drug administration) gastrointestinal disease with chronic or intermittent diarrhea.
• • Have an active bacterial, fungal, and/or known viral infection.
• • Have known acute or chronic leukemia or current hematologic malignancies that may affect the interpretation of results.